Shares of Correvio Pharma Corp. were halted in advance of a Food and Drug Administration advisory committee meeting for its experimental atrial fibrillation therapy. The drug, Brinavess, is already approved in Europe. The FDA is not required to follow the committee's recommendation but it often does. The FDA is expected to make its decision by Dec. 24. Correvio stock is down 43% year-to-date, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -1.08% has gained 25%.